NCT01633541 2023-07-20
Chemotherapy AND Bcl-xL Inhibitor (AT-101) For Organ Preservation In Adults With Advanced Laryngeal Cancer
University of Michigan Rogel Cancer Center
Phase 2 Completed
Clinical Trials
10 trialsNCT00540722 2017-08-11
Gossypol in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
National Cancer Institute (NCI)
Phase 2 Completed
NCT00666666 2014-12-18
R-(-)-Gossypol and Androgen Ablation Therapy in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00773955 2014-05-12
R-(-)-Gossypol Acetic Acid in Treating Patients With Recurrent Extensive-Stage Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00848016 2014-05-07
Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT00275431 2011-06-29
Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies
Ascenta Therapeutics
Phase 2 Completed
NCT00571675 2010-11-09
A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC)
Ascenta Therapeutics
Phase 2 Completed
NCT00440388 2010-08-27
Safety & Efficacy Study of AT-101 in Combination w/ Rituximab in Previously Untreated Grade I-II Follicular Non-Hodgkin's Lymphoma
Ascenta Therapeutics
Phase 2 Completed
NCT00544960 2010-08-27
A Randomized Phase 2 Study of AT-101 in Combination With Docetaxel in Relapsed/Refractory Non-Small Cell Lung Cancer
Ascenta Therapeutics
Phase 2 Completed
NCT00286780 2010-08-13
Phase 2 Safety and Efficacy Study of AT-101 in Combination With Rituximab in Patients With Chronic Lymphocytic Leukemia
Ascenta Therapeutics
Phase 2 Completed